1.50
2.04%
+0.03
Equillium Inc stock is currently priced at $1.50, with a 24-hour trading volume of 69,039.
It has seen a +2.04% increased in the last 24 hours and a +0.67% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.45 pivot point. If it approaches the $1.52 resistance level, significant changes may occur.
Previous Close:
$1.47
Open:
$1.5
24h Volume:
69,039
Market Cap:
$52.88M
Revenue:
$36.08M
Net Income/Loss:
$-13.34M
P/E Ratio:
-2.8302
EPS:
-0.53
Net Cash Flow:
$-21.83M
1W Performance:
+7.14%
1M Performance:
+0.67%
6M Performance:
+158.67%
1Y Performance:
+143.90%
Equillium Inc Stock (EQ) Company Profile
Name
Equillium Inc
Sector
Industry
Phone
858 412 5302
Address
2223 Avenida De La Playa, Suite 105, La Jolla, CA
Equillium Inc Stock (EQ) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-29-21 | Resumed | Stifel | Buy |
Sep-15-21 | Initiated | Cantor Fitzgerald | Overweight |
Jul-14-20 | Reiterated | H.C. Wainwright | Buy |
Jul-10-20 | Resumed | Stifel | Buy |
Feb-22-19 | Initiated | SVB Leerink | Outperform |
Equillium Inc Stock (EQ) Latest News
3 Biotech Stocks Under $20 Worth Watching in June - Entrepreneur
Entrepreneur
Decheng Capital LLC Makes New Investment in Equillium, Inc. (NASDAQ:EQ) - MarketBeat
MarketBeat
Equillium to Present at the Jefferies Global Healthcare Conference - Business Wire
Business Wire
Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus ... - br.ADVFN.com
br.ADVFN.com
Market Insights: Equillium Inc (EQ)'s financial ratios: A comprehensive overview – DWinneX - The Dwinnex
The Dwinnex
Biotech Rallies Strongly On Second Consecutive Positive Headline - The Globe and Mail
The Globe and Mail
Equillium Inc Stock (EQ) Financials Data
Equillium Inc (EQ) Revenue 2024
EQ reported a revenue (TTM) of $36.08 million for the quarter ending December 31, 2023.
Equillium Inc (EQ) Net Income 2024
EQ net income (TTM) was -$13.34 million for the quarter ending December 31, 2023, a +78.64% increase year-over-year.
Equillium Inc (EQ) Cash Flow 2024
EQ recorded a free cash flow (TTM) of -$21.83 million for the quarter ending December 31, 2023, a -142.27% decrease year-over-year.
Equillium Inc (EQ) Earnings per Share 2024
EQ earnings per share (TTM) was -$0.39 for the quarter ending December 31, 2023, a +79.47% growth year-over-year.
About Equillium Inc
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Cap:
|
Volume (24h):